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Abstract 
Background: The cardio‑ankle vascular index (CAVI) and brachial‑ankle pulse wave velocity (baPWV) can reflect both 
central and peripheral arterial stiffness. Metabolic syndrome (MetS) and its components may increase arterial stiffness 
and the risk of cardiovascular diseases. However, the correlation of MetS and its components with arterial stiffness is 
still not clear. The primary aim of this study is thus the relationship using baPWV and CAVI in Caucasian adults with 
intermediate cardiovascular risk. The secondary aim is to analyze sex differences.
Methods: This study analyzed 2351 subjects aged 35–74 years (mean, 61.4 ± 7.7 years) comprising 61.7 % males and 
enrolled in the improving interMediAte Risk management (MARK) study. CAVI was measured using a VaSera VS‑1500® 
device, and baPWV was calculated using a validated equation. MetS was defined based on the Joint Scientific State‑
ment National Cholesterol Education Program III. Waist circumference, blood pressure, fasting plasma glucose, and 
lipid profile were measured.
Results: MetS was found in 51.9 % of the subjects. All MetS components except reduced HDL‑cholesterol (p = 0.578) 
were associated with CAVI. High density lipoprotein cholesterol (p = 0.075) and waist circumference (p = 0.315) were 
associated with baPWV. The different MetS components that assess dyslipidemia using the stiffness measures show 
different associations according to patient sex. The high blood pressure component had a greater odds ratio (OR) for 
both baPWV ≥ 17.5 m/sec (OR = 6.90, 95 % CI 3.52–13.519) and CAVI ≥ 9 (OR = 2.20, 95 % CI 1.63–1.90).
Conclusions: MetS and all its components (except HDL‑cholesterol with baPWV and CAVI and WC with baPWV) were 
associated with baPWV and CAVI. However, there were sex differences in the association of MetS and its components 
with baPWV and CAVI. Data from this study suggest a greater association of CAVI and baPWV values with MetS com‑
ponents in males than in females and indicate greater arterial stiffness in the event of simultaneously elevated blood 
pressure, fasting plasma glucose, and waist circumference.
Trial Registration Clinical Trials.gov Identifier: https://clinicaltrials.gov/ct2/show/ NCT01428934. Registered 2 September 
2011. Last updated September 8, 2016
Keywords: Metabolic syndrome, Brachial‑ankle pulse wave velocity, Cardio‑ankle vascular index, Arterial stiffness
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  leticiagmzsnchz@gmail.com 
1 Primary Care Research Unit, The Alamedilla Health Center, 
37003 Salamanca, Spain
Full list of author information is available at the end of the article
Page 2 of 12Gomez‑Sanchez et al. Cardiovasc Diabetol  (2016) 15:148 
Background
Metabolic syndrome (MetS) is a cluster of multiple 
risk factors for atherosclerosis that include obesity, 
high blood pressure, elevated fasting plasma glucose 
(FPG), and atherogenic dyslipidemia [1]. MetS doubles 
the risk of morbidity and mortality from cardiovascu-
lar diseases and multiplies the risk of all-cause mortal-
ity by 1.5 [2–4]. However, the risk varies according to 
the associated components on which the MetS diagno-
sis is based [5]. For example, in the Framingham Heart 
Study cohort, the combination of central obesity, blood 
pressure (BP), and FPG increased the risk of mortal-
ity three-fold [6]. Similarly, different combinations of 
MetS components have different effects on arterial 
stiffness [7–9]. Several studies have also reported that 
greater arterial stiffness is associated with increased 
morbidity and mortality from cardiovascular diseases 
[10–12].
Arterial stiffness may be evaluated using the brachial-
ankle pulse wave velocity (baPWV) [13] and the car-
dio-ankle vascular index (CAVI) [14]. baPWV has been 
demonstrated as an independent predictor of coronary 
artery disease and all-cause mortality in general popula-
tions and in subjects with diabetes [15]. CAVI is a meas-
ure [14] of overall arterial stiffness starting from the aorta 
all the way to the ankle [16]. It is associated with carotid 
and coronary atherosclerosis [10, 17–19] and is a predic-
tor of cardiovascular events in the obese [10]. CAVI is a 
better predictor of coronary artery disease than baPWV 
[20, 21].
Studies have investigated the relationship of MetS 
and its components with baPWV [7, 22–24]. Most have 
reported increased baPWV in subjects with MetS or 
with a greater number of MetS components. Most of the 
studies have examined Asian populations, among whom 
MetS and its components affect arterial stiffness with 
greater severity in females than in males [23, 25]. It is 
likely that females with MetS develop more severe ather-
osclerosis, but this is not yet definitive [25]. Furthermore, 
the sex-dependent association of the specific cluster of 
MetS components with baPWV and CAVI in Caucasian 
adults with intermediate cardiovascular risk has not been 
previously.
Research on the relationship of MetS and its com-
ponents with baPWV and CAVI is an important topic 
around the world. Unlike baPWV, the characteristics of 
CAVI as a physiological marker of arterial stiffness have 
not frequently been reported. The primary aim of this 
study is to investigate the relationship of MetS and its 
components with arterial stiffness measured by baPWV 
and CAVI in Caucasian adults with intermediate cardi-




This trial is a cross-sectional study of subjects recruited 
to the improving interMediAte RisK management 
(MARK) study (NCT01428934) [26], which is a longitu-
dinal study designed to assess whether the ankle-brachial 
index, arterial stiffness (measured by CAVI), postprandial 
glucose, glycosylated hemoglobin, self-measured blood 
pressure, and the presence of comorbidities are indepen-
dently associated with the occurrence of vascular events. 
It also investigates whether the predictive capacity of cur-
rent risk equations can be improved in the intermediate 
risk population. The current study focuses on the base-
line visit. The second step will be a 5- and 10 year follow-
up trial to assess cardiovascular morbidity and mortality.
Study population
In this multicenter project, sample selection was per-
formed by random sampling from among individuals 
who met the inclusion criteria and were seeing general 
practitioners at six primary care centers in three Span-
ish Autonomous Communities from July 2011 to June 
2013. Subjects were recruited from those aged 35 to 
74  years with intermediate cardiovascular risk defined 
as 10 year coronary risk ranging from 5–15 % according 
to the adapted Framingham risk equation [27]; 10  year 
vascular mortality risk ranging from 1–5 % according to 
the scoring risk in Europeans equation [28]; or moderate 
risk according to the European Society of Hypertension 
guidelines for the management of arterial hypertension 
[29]. The analysis examined 2351 of the 2495 subjects 
recruited to the MARK study. Exclusion criteria included 
end-stage disease or institutionalization at the time of the 
visit, or a history of atherosclerotic disease. Subjects were 
excluded for the following reasons: 88 had an altered 
ankle-brachial index, measured CAVI and/or baPWV 
values were not available for 23 subjects, and MetS com-
ponents had not been measured for 33 subjects. The 
study was approved by the Research Ethics Commit-
tees of the Primary Care Research Institute of Jordi Gol, 
Health Care Area of Salamanca and Palma of Mallorca. 
All participants gave written informed consent accord-
ing to the general recommendations of the Declaration of 
Helsinki [30].
Variables and measurement instruments
A detailed description of procedures for clinical data col-
lection, anthropometric measurements, and laboratory 
tests has been published elsewhere [26].
Diagnostic criteria of MetS
According to the international consensus in the 
Joint Scientific Statement National Cholesterol 
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Education Program III [1], MetS was defined as the 
presence of three or more of the following five com-
ponents: abdominal obesity (waist circumference 
(WC)  ≥88  cm in females and  ≥102  cm in males); ele-
vated triglycerides (TGC)  ≥150  mg/dL (or drug treat-
ment for elevated TGC); high-density lipoprotein 
(HDL) cholesterol  <40  mg/dL in males or  <50  mg/dL 
in females; high blood pressure (systolic blood pres-
sure (SBP)  ≥130  mmHg or diastolic blood pressure 
(DBP) ≥85 mmHg, or antihypertensive drug treatment), 
and fasting plasma glucose (FPG) ≥100 mg/dL (or drug 
treatment for elevated glucose).
Analysis groups
In order to analyze the influence of the different com-
binations of MetS components upon arterial stiffness, 
the subjects were divided into three groups. The group 
“MetS-dyslipidemia” consisted of 367 subjects with com-
ponents of high blood pressure and those that indicate 
dyslipidemia (low HDL-cholesterol and elevated triglyc-
erides). The group “MetS-increased insulin resistance” 
consisted of 511 subjects with the components of high 
blood pressure and those that indicate increased insulin 
resistance (elevated FPG and abdominal obesity). The 
group “MetS-mixed” consisted of 342 subjects with MetS 
who were not included in either the dyslipidemia group 
or the increased insulin resistance group. The control 
group consisted of 175 subjects without MetS, arterial 
hypertension, FPG, or the use of antihypertensive, lipid-
lowering, or antidiabetic drugs.
Diagnosis of cardiovascular risk factors
Subjects were considered hypertensive if previously 
diagnosed with hypertension, if they were taking anti-
hypertensive drugs, or if they had blood pressure lev-
els  ≥140/90  mmHg. Diabetic subjects were those who 
had a previous diagnosed of the disease, were tak-
ing hypoglycemic drugs, or had fasting blood glucose 
levels  ≥126  mg/dL or HbA1c  ≥6.5  %. Dyslipidemia 
was defined as a prior diagnosis of the condition, use 
of lipid-lowering drugs, or fasting total cholesterol 
levels ≥250 mg/dL.
Cardio‑ankle vascular index (CAVI) and brachial‑ankle 
pulse wave velocity (baPWV)
CAVI was measured using a VaSera VS-1500® device 
(Fukuda Denshi) [31, 32]. CAVI values are calculated 
automatically by estimating the stiffness parameter β 
with the following equation: β  =  2ρ ×  1/(Ps−Pd) ×  ln 
(Ps/Pd) × PWV2, where ρ is blood density, Ps and Pd are 
SBP and DBP in mmHg, and PWV is measured between 
the aortic valve and the ankle [14]. The mean coefficient 
of variation of CAVI measurement is less than 5 %, which 
is small enough to allow for clinical use of the index and 
confirms that CAVI has a favorable reproducibility [32].
baPWV was estimated using the equation, 
baPWV =  (0.5934 ×  height (cm) +  14.4724)/tba (tba 
is the time interval between the arm and ankle waves) 
[13]. Measurements were performed with the patient 
in supine position after resting for 10  min in a quiet 
room at a stable temperature. Subjects were instructed 
not to smoke or practice exercise in the hour prior to 
the test.
CAVI was classified as normal (CAVI < 8), borderline 
(8  ≤  CAVI  <  9), or abnormal (CAVI  ≥  9). Abnormal 
CAVI represents subclinical atherosclerosis [14, 33–36]. 
A value of baPWV ≥17.5  m/sec was considered abnor-
mal [37]. The average values of CAVI and baPWV were 
considered.
Office or clinical blood pressure
Office blood pressure measurement involved three meas-
urements of SBP and DBP with a validated OMRON 
model M10-IT sphygmomanometer (Omron Health 
Care, Kyoto, Japan). The measurements followed the rec-
ommendations of the European Society of Hypertension 
[38], and the averages of the last two measurements used.
Anthropometric measurements
Body weight was measured twice with a certified elec-
tronic scale (Seca 770, Medical scale and measurement 
systems, Birmingham, United Kingdom) after adequate 
calibration (precision  ±0.1  kg). Readings were rounded 
to 100 g. Height was measured with a stadiometer (Seca 
222), and the average of two measurements was recorded. 
Body mass index (BMI) was calculated as weight (kg) 
divided by height squared (m2). Waist circumference was 
measured according to the 2007 recommendations of the 
Spanish Society for the Study of Obesity [39]. All meas-
urements were performed with the subjects standing, 
wearing no shoes, and in light clothing. The researchers 
who performed the different tests were blinded to the 
clinical data of the subjects. All assessments were made 
within a period of 10 days.
Statistical analysis
Continuous variables are expressed as the mean ± stand-
ard deviation. Categorical variables are presented as 
frequency distributions and compared using the Chi-
squared test or Fisher’s exact test when necessary. The 
difference in means between 2-category and quantitative 
variables was analyzed using the student’s t test for inde-
pendent samples. ANCOVA models were used to test the 
differences in mean baPWV and CAVI values with the 
five components of MetS. Pairwise post hoc comparisons 
were examined using the Bonferroni test.
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In the multivariate analysis, six multiple linear regres-
sion models were performed (ENTER method) using 
CAVI and baPWV as dependent variables and MetS 
and its components as independent variables of each 
model. Six logistic regression models were also devel-
oped in which baPWV (<17.5 =  0 and ≥17.5 =  1) and 
CAVI status (<9 = 0 and ≥9 = 1) were dependent vari-
ables, while the independent variables were the absence 
(0) or presence (1) of MetS and its components. All mod-
els included age, height, weight, antihypertensive drugs, 
lipid-lowering drugs, and antidiabetic drugs as adjusting 
variables. The exception was WC, which was adjusted for 
age and drug use because of collinearity problems. Anal-
yses were performed for the subjects overall and accord-
ing to gender. Data were analyzed using SPSS Statistics 
for Windows version 23.0 (IBM Corp, Armonk, NY). Val-
ues of p < 0.05 were considered statistically significant.
Results
Clinical characteristics of all subjects
Table  1 shows the characteristics (overall and by 
sex) of the 2351 subjects analyzed. Mean age was 
61.4 ±  7.7  years. MetS was found in 51.9 % of the sub-
jects (46.0 % of males and 61.4 % of females). The mean 
baPWV was 14.9  ±  2.6  m/sec (coefficient of variation: 
0.172), and the mean CAVI was 8.8 ± 1.2 (coefficient of 
variation: 0.133). CAVI was higher among males than 
females (8.9  ±  1.2 versus 8.6  ±  1.1; p  <  0.001). Mean 
baPWV values were similar among both sexes.
Table  2 shows differences between subjects with and 
without MetS by sex. baPWV was higher in subjects with 
MetS, regardless of sex. Mean CAVI values were not dif-
ferent between subjects with and without MetS in either 
sex.
Association between the MetS and its components 
with arterial stiffness
After adjustment for potentially influencing variables, 
a multiple linear regression analysis showed that almost 
all MetS components were associated with baPWV and 
CAVI except for reduced HDL-cholesterol with respect 
to CAVI (p =  0.578) and baPWV (p =  0.075) and WC 
with respect to baPWV (p  =  0.315). Among males, all 
MetS components (except HDL-cholesterol with respect 
to CAVI and WC with respect to baPWV) were associ-
ated with the two arterial stiffness measures. However, 
among females, SBP, DBP, and FPG were associated with 
baPWV and CAVI, and WC was associated with CAVI 
(Table 3).
The association persisted in the disaggregated analy-
sis in subjects with and without antihypertensive, lipid-
lowering, and antidiabetic treatments. The exceptions 
were the correlation between triglycerides and CAVI 
and baPWV, which was only seen in the treated subjects, 
and WC, which was only associated with baPWV in the 
untreated individuals and with CAVI in the drug treat-
ment group (Additional file 1: Table S1).
The results of the multiple regression analysis of pre-
menopausal and postmenopausal women and males over 
and under 50 years of age are shown in Additional file 1: 
Table 2S.
In a logistic regression analysis and after adjusting for 
potentially influencing variables, the component of MetS 
with the greatest odds ratio (OR) was high blood pressure 
for both baPWV ≥ 17.5 m/sec (OR = 6.90, 95 % CI 3.52–
13.51) and CAVI  ≥  9 (OR  =  2.20, 95  % CI 1.63–1.90) 
(Table 4).
Results for subjects with MetS
Figure  1 shows the mean values corresponding to 
baPWV and CAVI according to sex and for each of the 
components of MetS. In the 1220 subjects with MetS, all 
the MetS components presented higher baPWV values in 
females except for waist circumference (p > 0.05). How-
ever, all the MetS components presented higher CAVI 
values in males, reaching significant differences in the 
case of the components related to increased blood pres-
sure, fasting plasma glucose, and waist circumference.
Figure 2 shows the change in mean baPWV and CAVI 
values after age adjustment for increasing number of 
MetS components. The mean baPWV values in females 
increased with the number of MetS components. How-
ever, in males, the mean baPWV values increased for only 
up to three MetS components. The mean CAVI values in 
females increased with two, three, and four MetS compo-
nents. However, in males, CAVI values increased for up 
to three MetS components but decreased in groups with 
four or five components.
The results for the mean baPWV and CAVI values 
according to groups are shown in Additional file 2: Fig. S1 
and Fig. 3. The MetS-increased insulin resistance group 
had the highest CAVI (8.96) and baPWV (15.55  m/sec) 
in both the global analysis and the sex-based analysis. In 
the global analysis, all groups of MetS components were 
associated with higher baPWV and CAVI values com-
pared to the control group (p < 0.01), except for CAVI in 
the MetS-mixed group.
Discussion
The results show that in subjects with intermediate car-
diovascular risk, MetS and its individual components 
(except HDL-cholesterol with the two measures and WC 
with baPWV) are associated with baPWV and CAVI. 
This association differs according to sex. In males, all 
MetS components (except HDL-cholesterol with CAVI 
and WC with baPWV) were associated with both arterial 
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stiffness measures. In females only, SBP, DBP, and FPG 
were associated with both measures, and WC was associ-
ated with CAVI. The arterial stiffness values were highest 
when the MetS components of increased blood pressure, 
FPG, and WC occurred simultaneously.
FPG was associated with higher baPWV (15.50  m/
sec) and CAVI (9.01) in females and males, respec-
tively. Subjects in this study who had a combination of 
increased WC, FPG, and BP showed the highest values 
of both arterial stiffness measures. This finding is Simi-
lar to the results of the Framingham Heart Study cohort, 
where this combination increased the risk of mortality by 
three-fold [6]. These results suggest that analyzing arte-
rial stiffness in these groups may be helpful for identify-
ing subjects with greater cardiovascular risk [9].
A single study analyzed the relationship of CAVI to 
MetS and its components. Kawada et  al. [24] found no 
significant association between MetS components and 
CAVI ≥ 9, with which only sex and age were significantly 
associated. However, our results suggest that the associa-
tion of MetS and its components with CAVI is similar to 
the association with baPWV. These differences are prob-
ably due to the study size (144 subjects) and the differ-
ent ethnic groups of the samples. On the other hand, in a 
Table 1 Characteristics of subjects global and stratified by gender
Values are means (standard deviations (SD) for continuous data and number and proportions for categorical data
Metabolic syndrome: Three or more of the following criteria: (Abdominal obesity = Higher WC: waist circumference ≥88 in females and ≥102 in males. Higher blood 
pressure: SBP ≥130 mmHg and/or DBP ≥85 mmHg or antihypertensive drug treatment. Higher FPG: FPG >100 mg/dl or antidiabetic drug treatment. Lower HDL 
cholesterol: HDL cholesterol <40 mg/dl in males and <50 mg/dl in females. Higher triglycerides: TGC >150 mg/dl)
BMI body mass index; WC waist circumference; SBP systolic blood pressure; DBP diastolic blood pressure; LDL-C low density lipoprotein cholesterol; HDL-C high density 
lipoprotein cholesterol; TGC triglycerides; FPG fasting plasma glucose; HbA1c glycosylated hemoglobin; CAVI cardio‑ankle vascular index; baPWV brachial‑ankle pulse 
wave velocity
p value differences in male and females
Variables Global (n = 2351) Males (n = 1450) Females (n = 901) p value
Age, (years) 61.4 ± 7.7 61.2 ± 8.1 61.8 ± 7.0 0.044
Smoking, n (%) 659 (28.1) 455 (31.4) 204 (22.7) <0.001
BMI, (kg/m2) 29.2 ± 4.4 29.1 ± 3.9 29.5 ± 5.1 0.016
BMI ≥ 30, n (%) 850 (36.2) 485 (33.4) 365 (40.5) 0.001
WC, (cm) 100.9 ± 11.6 102.9 ± 10.5 97.6 ± 12.5 <0.001
SBP, (mmHg) 137.0 ± 17.4 138.9 ± 17.1 134.1 ± 17.5 <0.001
DBP, (mmHg) 84.4 ± 10.2 85.5 ± 10.3 82.6 ± 9.6 <0.001
Hypertension, n (%) 1842 (78.3) 1163 (80.2) 679 (75.4) 0.006
Antihypertensive drugs, n (%) 1208 (51.4) 733 (50.6) 475 (52.7) 0.309
Total Cholesterol, (mg/dl) 225.7 ± 41.0 220.6 ± 38.0 233.9 ± 42.8 <0.001
LDL‑C, (mg/dl) 140.4 ± 34.9 138.9 ± 34.2 142.7 ± 35.8 0.010
HDL Cholesterol, (mg/dl) 49.8 ± 12.9 47.9 ± 11.9 52.9 ± 13.8 <0.001
TGC, (mg/dl) 145.7 ± 97.0 150.5 ± 106.7 138.0 ± 78.2 0.002
Dyslipidemia, n (%) 1583 (67.3) 924 (63.7) 659 (73.1) <0.001
Lipid lowering drugs, n (%) 673 (28.6) 392 (27.0) 281 (31.2) 0.031
FPG, (mg/dl) 107.7 ± 34.4 107.4 ± 33.5 108.0 ± 35.9 0.711
HA1c, (%) 6.1 ± 1.2 6.1 ± 1.1 6.2 ± 1.3 0.001
Diabetes mellitus type 2, n (%) 794 (33.8) 464 (32.0) 330 (36.6) 0.022
Antidiabetic drugs, n (%) 477 (20.3) 270 (18.6) 207 (23.0) 0.015
Higher blood pressure, n (%) 1986 (84.5) 1253 (86.4) 733 (81.4) 0.001
Higher FPG, n (%) 1112 (47.3) 693 (47.8) 419 (46.5) 0.552
Lower HDL‑C, n (%) 791(33.6) 357 (24.6) 434 (48.2) <0.001
Higher TGC, n (%) 839 (35.7) 545 (37.6) 294 (32.6) 0.015
Higher WC, n (%) 1478 (62.9) 762 (52.6) 716 (79.5) <0.001
Metabolic syndrome, n (%) 1220 (51.9) 667 (46.0) 553 (61.4) <0.001
CAVI 8.80 ± 1.17 8.91 ± 1.19 8.65 ± 1.12 <0.001
CAVI ≥ 9, n (%) 1061 (45.1) 701 (49.6) 360 (41.3) 0.001
baPWV, (m/s) 14.87 ± 2.57 14.81 ± 2.56 14.98 ± 2.59 0.119
baPWV ≥ 17.50 m/s, n (%) 324 (13.8) 192 (13.2) 132 (13.9) 0.356
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Japanese population, CAVI was shown to be a predictor 
of cardiovascular events in obese subjects (MetS com-
ponent) in the Japan Obesity and Metabolic Syndrome 
study [10]. It should not be forgotten, however, that this 
is the first study analyzing the association of each MetS 
component with two arterial stiffness measures and 
adjustment for different confounding factors in a large 
simple of subjects at intermediate cardiovascular risk.
The results do not coincide with those published 
by Satoh et  al. [31] for 325 obese Japanese subjects 
enrolled in the multicenter Japan Obesity and Meta-
bolic Syndrome Study. Their CAVI values were signifi-
cantly higher in MetS than in non-MetS subjects, and 
CAVI was closely correlated with the severity of MetS. 
The discrepancies with our results may have several 
reasons: the subjects analyzed in this study were older 
(61.4 versus 49.4 years), and the most prevalent compo-
nent of MetS in our group was blood pressure (a com-
ponent less associated with CAVI than other stiffness 
measures). Other aspects are the different race, cardio-
vascular risk, and the drugs used for treatment of the 
different risk factors.
The subjects with arterial hypertension presented a six-
fold higher risk of baPWV ≥  17.5 m/sec, while the risk 
of CAVI  ≥  9 increased two-fold. These results support 
several studies [14, 40–42], according to which CAVI 
as an arterial stiffness measure is independent of blood 
pressure at the time of measurement. In relation to the 
rest of the MetS components, the odds ratios were simi-
lar for both stiffness measures, although increased waist 
circumference and low HDL-cholesterol only reached 
statistical significance with CAVI. This was probably due 
to the greater percentage of subjects with CAVI ≥ 9.
The MetS components BP and TGC were more com-
mon in males, and the WC and HDL cholesterol compo-
nents were more common in females, while no difference 
was found in FPG. These results are similar to those 
reported for a Spanish population in the DARIOS study 
Table 2 Characteristics of subjects stratified by gender and the presence/absence of metabolic syndrome
Values are means (standard deviations (SD) for continuous data and number and proportions for categorical data
Metabolic syndrome: Three or more of the following criteria: (abdominal obesity = higher WC: waist circumference ≥88 in females and ≥102 in males. Higher blood 
pressure: SBP ≥130 mmHg and/or DBP ≥85 mmHg or antihypertensive drug treatment. Higher FPG: FPG >100 mg/dl or antidiabetic drug treatment. Lower HDL 
cholesterol: HDL cholesterol <40 mg/dl in males and <50 mg/dl in females. Higher triglycerides: TGC >150 mg/dl)
MetS metabolic syndrome; SBP systolic blood pressure; DBP diastolic blood pressure; HDL-C high density lipoprotein cholesterol; TGC triglycerides; FPG fasting plasma 
glucose; WC waist circumference; CAVI cardio‑ankle vascular index; baPWV brachial‑ankle pulse wave velocity
* p < 0.05 in males, † p < 0.05 in females
Variables Males subjects (n = 1450) Females subjects (n = 901)
MetS + n = 667 MetS − n = 783 MetS + n = 553 MetS − n = 348
Age, (years)* 60.5 ± 8.1 61.8 ± 8.1 61.7 ± 7.1 62.1 ± 6.9
SBP, (mmHg)*† 141.4 ± 16.1 136.7 ± 17.5 136.3 ± 17.1 130.6 ± 17.7
DBP. (mmHg)*† 87.5 ± 10.3 83.7 ± 10.1 83.5 ± 9.2 81.2 ± 10.2
Hypertension, n (%)*† 600 (90.0) 563 (71.9) 469 (84.8) 210 (60.3)
Antihypertensive drugs, n (%)*† 404 (60.6) 329 (42.0) 352 (63.7) 123 (35.3)
HDL‑C, (mg/dl)*† 43.2 ± 10.3 51.9 ± 11.8 48.3 ± 11.2 60.3 ± 14.2
TGC, (mg/dl)*† 184.0 ± 132.4 116.8 ± 54.0 160.8 ± 87.9 101.8 ± 37.5
Dyslipidemia, n (%) 436 (65.4) 488 (62.3) 403 (72.9) 256 (73.6)
Lipid lowering drugs, n (%)*† 207 (31.0) 185 (23.6) 197 (35.6) 84 (24.1)
FPG (mg/dl)*† 118.6 ± 37.9 98.0 ± 25.8 118.2 ± 39.3 91.8 ± 21.3
Diabetes mellitus type 2, n (%)*† 329 (49.3) 135 (17.2) 289 (52.3) 41 (11.8)
Antidiabetic drugs, n (%)*† 198 (29.7) 72 (9.2) 188 (34.0) 19 (5.5)
WC, (cm)*† 108.3 ± 10.1 98.3 ± 8.5 101.5 ± 11.3 91.4 ± 11.6
Higher blood pressure, n (%)*† 644 (96.6) 609 (77.8) 512 (92.6) 221 (63.5)
Higher FPG, n (%)*† 494 (74.1) 199 (25.4) 378 (68.4) 41 (11.8)
Lower HDL‑C, n (%)*† 295 (44.2) 62 (7.9) 372 (67.3) 62 (17.8)
Higher TGC, n (%)*† 423 (63.4) 122 (15.6) 269 (48.6) 25 (7.2)
Higher WC, n (%)*† 539 (80.8) 223 (28.5) 516 (93.3) 200 (57.5)
CAVI 8.86 ± 1.24 8.94 ± 1.14 8.66 ± 1.19 8.61 ± 1.01
CAVI ≥ 9, n (%) 319 (49.3) 382 (49.9) 230 (42.8) 130 (38.9)
baPWV, (m/s)*† 14.98 ± 2.50 14.66 ± 2.61 15.23 ± 2.59 14.60 ± 2.36
baPWV ≥ 17.5 m/s, n (%) 94 (14.1) 98 (12.5) 97 (17.5) 35 (10.1)
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Table 3 Associations of MetS components with baPWV and CAVI values global and by gender
Multiple linear regression models were used to analyze the associations of components of MetS to baPWV and CAVI values, globally and stratified by gender. Age, 
height, weight, antihypertensive drugs, lipid‑lowering drugs and antidiabetic drugs were adjusted in the regression models. The exception was WC, which was 
adjusted for age and drug use because of collinearity problems
MetS metabolic syndrome; baPWV brachial‑ankle pulse wave velocity; CAVI cardio‑ankle vascular index; CI confidence interval; R2 Coefficient of determination; 
SBP systolic blood pressure; DBP diastolic blood pressure; HDL-C high density lipoprotein cholesterol; TGC triglycerides; FPG fasting plasma glucose; WC waist 
circumference
Components MS Global (n = 2351) Males subjects (n = 1450) Females subjects (n = 901)
β (95 % CI) R2 p value β (95 % CI) R2 p value β (95 % CI) R2 p value
Dependent variable: baPWV
SBP, (mmHg) 0.062 (0.056 to 0.066) 0.371 <0.001 0.061 (0.055 to 0.067) 0.352 <0.001 0.061 (0.053 to 0.069) 0.397 <0.001
DBP, (mmHg) 0.082 (0.072 to 0.090) 0.299 <0.001 0.077 (0.066 to 0.089) 0.281 <0.001 0.085 (0.071 to 0.100) 0.329 <0.001
HDL‑C, (mg/dl) 0.007 (−0.001 to 0.015) 0.206 0.075 0.012 (0.002 to 0.023) 0.196 0.003 0.012 (−0.008 to 0.014) 0.233 0.561
TGC, (mg/dl) 0.002 (0.001 to 0.003) 0.209 0.001 0.002 (0.001 to 0.003) 0.198 0.002 0.001 (−0.001 to 0.003) 0.234 0.182
FPG, (mg/dl) 0.007 (0.004 to 0.010) 0.210 <0.001 0.005 (0.001 to 0.009) 0.198 0.031 0.010 (0.005 to 0.015) 0.244 0.001
WC, (cm) −0.004 (−0.012 to 0.004) 0.200 0.315 −0.002 (−0.014 to 0.009) 0.185 0.679 −0.007 (−0.019 to 0.005) 0.226 0.269
Dependent variable: CAVI
SBP, (mmHg) 0.015 (0.013 to 0.017) 0.398 <0.001 0.016 (0.013 to 0.018) 0.430 <0.001 0.014 (0.011 to 0.018) 0.327 <0.001
DBP, (mmHg) 0.020 (0.017 to 0.024) 0.377 <0.001 0.022 (0.017 to 0.026) 0.414 <0.001 0.017 (0.011 to 0.024) 0.302 <0.001
HDL‑C, (mg/dl) −0.001 (−0.004 to 0.002) 0.348 0.578 0.002 (−0.003 to 0.006) 0.382 0.486 −0.002 (−0.007 to 0.002) 0.282 0.301
TGC, (mg/dl) 0.001 (0.001 to 0.001) 0.351 0.002 0.001 (0.001 to 0.001) 0.286 0.002 0.001 (0.001 to 0.001) 0.382 0.289
FPG, (mg/dl) 0.003 (0.002 to 0.005) 0.355 <0.001 0.003 (0.001 to 0.005) 0.387 0.002 0.004 (0.002 to 0.006) 0.289 0.001
WC, (cm) −0.013 (−0.016 to −0.009) 0.290 <0.001 −0.017 (−0.021 to −0.012) 0.354 <0.001 −0.017 (−0.023 to −0.012) 0.236 <0.001
Table 4 Multiple logistic regression analysis of  associations between  MetS/components and  baPWV and  CAVI status 
in males and females
Dependent variable: CAVI and baPWV (values of CAVI ≥9 and baPWV ≥17.5 m/s was considered abnormal)
Multiple logistic regression analysis was used to analyze the associations of MetS status and MetS components with baPWV and CAVI globally and stratified by gender. 
Age, height, weight, antihypertensive drugs, lipid‑lowering drugs and antidiabetic drugs were adjusted in the regression models. The exception was WC, which was 
adjusted for age and drug use because of collinearity problems
MetS metabolic syndrome; baPWV brachial‑ankle pulse wave velocity; CAVI cardio‑ankle vascular index; OR odds ratio; CI confidence interval; BP blood pressure; FPG 
fasting plasma glucose; TGC triglycerides; HDL-C high density lipoprotein cholesterol; WC waist circumference
Components MetS Global (n = 2351) Males subjects (n = 1450) Females subjects (n = 901)
OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value
Dependent variable: baPWV
High BP 6.899 (3.522 to 13.511) <0.001 7.578 (2.975 to 19.345) <0.001 5.272 (1.975 to 19.345) <0.001
High FPG 1.527 (1.123 to 2.077) 0.007 1.290 (0.875 to 1.902) 0.199 2.035 (1.221 to 3.392) 0.006
High TGC 0.745 (0.559 to 0.992) 0.044 0.738 (0.480 to 1.135) 1.116 0.802 (0.534 to 1.205) 0.287
Low HDL‑C 1.202 (0.915 to 1.579) 0.186 1.159 (0.811 to 1.656) 0.419 1.329 (0.863 to 2.248) 0.197
High WC 0.965 (0.743 to 1.254) 0.792 0.874 (0.633 to 1.207) 0.414 1.149 (0.675 to 1.953) 0.609
MetS 1.421 (1.062 to 1.902) 0.018 1.512 (1.032 to 2.215) 0.034 1.679 (1.019 to 2.765) 0.042
Dependent variable: CAVI
High BP 2.204 (1.629 to 2.983) <0.001 2.238 (1.499 to 3.339) <0.001 2.115 (1.320 to 3.338) 0.002
High FPG 1.368 (1.090 to 1.718) 0.007 1.401 (1.052 to 1.866) 0.021 1.256 (0.857 to 1.842) 0.242
High TGC 0.931 (0.755 to 1.147) 0.500 1.031 (0.768 to 1.384) 0.839 0.888 (0.651 to 1.213) 0.457
Low HDL‑C 1.283 (1.043 to 1.579) 0.018 1.374 (1.054 to 1.792) 0.019 1.166 (0.832 to 1.633) 0.372
High WC 0.686 (0.565 to 0.834) <0.001 0.786 (0.617 to 1.001) 0.051 0.741 (0.511 to 1.075) 0.115
MetS 1.543 (1.235 to 1.927) <0.001 1.723 (1.286 to 2.307) <0.001 1.424 (0.990 to 2.048) 0.056
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[43], but different from those reported in Asian popula-
tions [5, 7]. Prior studies support these results [7, 25]. 
Previous studies also analyzed the different behavior of 
arterial stiffness depending on sex [25, 44]. They found 
that stiffness was greater in females than males before 
puberty and increased after menopause. On the other 
hand, males arterial stiffness increases linearly from 
puberty, which suggests that women have intrinsically 
stiffer major arteries than men, but these effects are 
mitigated by sex steroids during reproductive life [45, 
46]. Other factors that may influence these sex differ-
ences include height [47], body fat distribution [48], and 
inflammatory factors [49]. The tool used to assess arterial 
stiffness may also have an influence. The reason may be 
that CAVI reflects central and peripheral arterial stiffness 
[14, 50, 51] and is less influenced by BP values at the time 
of measurement [14, 40–42]. Arterial stiffness assessed 
with baPWV, however, is a measure of peripheral arterial 
stiffness.
The effects of MetS and its components on baPWV 
are not clear. Several studies on Eastern populations 
have shown that they are more evident in females than 
in males [7, 25]. Scuteri et al. [52] reported the impact of 
MetS on arterial stiffness to be similar in both sexes, and 
in this study, the number of MetS components associ-
ated with arterial stiffness measures was greater in males. 
However, baPWV and CAVI increased proportionally as 
the number of components increased in females, which 
occurred in other studies conducted on Asian popula-
tions [7, 8, 23, 25], but not in males. The different char-
acteristics of the populations analyzed and the arterial 
stiffness measurement based on different parameters 
may explain these discrepancies.
Each component of MetS has a clear sex-dependent 
impact on baPWV [52]. As in other studies [7, 47], BP 
and especially SBP had the greatest association with 
baPWV and CAVI in our study, in contrast to all other 
components [25, 52]. Prior studies showed a positive cor-
relation of HDL-C with baPWV in females only [7, 25]. 
In this study, HDL cholesterol and TGC levels correlated 
with baPWV in males only, and only TGC correlated with 
CAVI in males, which is in agreement with the results 
reported by Weng et al. [25]. However, low HDL choles-
terol levels [53] and high TGC levels [54] are predictors 
of morbidity and mortality from cardiovascular diseases. 
Further studies analyzing the role of HDL cholesterol and 
TGC in arterial stiffness are therefore needed.
FPG induces many changes in vascular tissue cells, 
which may potentially accelerate the atherosclerotic 
process (mainly in females) [23, 55, 56]. This supports 
our results found in our study. Abdominal obesity is 
an essential element in MetS [57] and shows a negative 
association with CAVI in both sexes. Unlike our work, 
the association of baPWV with WC has been recorded 
in both sexes in Asian populations [23, 25]. These differ-
ences are related to the adjustment variables used.
The greater decrease in CAVI among the subjects with 
more MetS components could be due to the lesser influ-
ence of blood pressure on CAVI [14, 40–42]. Another 
possible explanation is the greater percentage of sub-
jects receiving drug treatment in the groups with 4 or 5 
MetS components. Thus, while 44 % of the subjects in the 
group with 0 or 1 component were receiving drugs for 
hypertension, diabetes, or dyslipidemia, the correspond-
ing percentages were 77 and 88  % among the subjects 
with 4 and 5 MetS components, respectively.
Our results suggest that in Caucasian subjects with 
intermediate cardiovascular risk, arterial stiffness is 
associated with the MetS components, except HDL-
cholesterol for baPWV and CAVI and WC for baPWV 
except for HDL-cholesterol with respect to both stiff-
ness parameters and waist circumference with respect 
Fig. 1 baPWV a and CAVI b according the MetS components in 
males and females. Data are given as mean ± standard error. baPWV 
and CAVI levels were compared using a Student’s t test. Mest criteria: 
abdominal obesity (n = 1055): WC ≥ 88 in females; ≥ 102 in males. 
BP (n = 1156): SBP ≥ 130 mmHg and/or DBP ≥ 85 mm Hg or antihy‑
pertensive drug treatment. Increase FPG (n = 872): FPG > 100 mg/
dL or antidiabetic drug treatment. Reduced HDL‑C (n = 667): 
HDL < 40 mg/dL in males and < 50 mg/dL in females. Increase TGC 
(n = 692): TGC > 150 mg/dL). baPWV brachial‑ankle pulse wave 
velocity, CAVI cardio‑ankle vascular index, BP blood pressure, FPG 
fasting plasma glucose, HDL-C high density lipoprotein cholesterol, 
TGC triglycerides, WC waist circumference. *p < 0.05 and **p < 0.01 
between sexes
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Fig. 2 Multivariate analysis (ANCOVA). Brachial‑ankle pulse wave velocity (baPWV) values in males and females (a) and cardio‑ankle vascular index 
(CAVI) values in males and females (b). Values by number of MetS components. Adjusted by age. baPWV differences by number of MetS compo‑
nents in males between 0 and 1 components and 2, 3, and 4 components (p < 0.01); in females between 1 component and 3, 4, and 5 components 
(p < 0.01). Post‑hoc contrasts were performed using a Bonferroni test. baPWV brachial‑ankle pulse wave velocity, CAVI cardio‑ankle vascular index, 
MetS metabolic syndrome
Fig. 3 Impact of the specific groups of MetS components on brachial‑ankle pulse wave velocity (baPWV) and cardio‑ankle vascular index (CAVI) in 
the different groups. a Impact of the group in females on baPWV. b Impact of the group in males on baPWV. c Impact of the group in females on 
CAVI. d Impact of the group in males on CAVI. Data are given as mean ± standard error. baPWV and CAVI levels were compared using an ANOVA 
test, followed by post hoc analysis using a Bonferroni test. **p < 0.01 between the different groups and control; *p < 0.05 between the different 
groups and control. Group 1 Group MetS‑mixed; Group 2 MetS‑dyslipidemia; Group 3 Group MetS‑increased insulin resistance; Group Control A group 
of 175 subjects without MetS, arterial hypertension, FPG or use of antihypertensive, lipid‑lowering or antidiabetic drugs was used as control. baPWV 
brachial‑ankle pulse wave velocity, CAVI cardio‑ankle vascular index, MetS metabolic syndrome, FPG fasting plasma glucose
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to baPWV. However, the association of triglycerides and 
HDL-cholesterol was only observed in males. These dif-
ferences could have clinical relevance and may help to 
explain the discrepancies in cardiovascular risk between 
sexes. The results suggest that the treatment of hypertri-
glyceridemia could improve arterial stiffness, particularly 
in males with MetS.
The main limitation of our study is its cross-sectional 
design, which cannot establish causal relations or the 
direction of the impact of MetS on CAVI and baPWV. 
An additional limitation is the impact on arterial stiffness 
of drugs for treating specific MetS components such as 
blood glucose, dyslipidemia, and blood pressure. How-
ever, we did try to mitigate this effect by including them 
as adjustment variables in the regression analysis.
Conclusions
MetS and most of its individual components (except 
HDL-cholesterol for baPWV and CAVI and WC for 
baPWV) were associated with baPWV and CAVI. How-
ever, there were differences between sex in the asso-
ciation of MetS and its components with baPWV and 
CAVI. The data suggest a greater association of CAVI 
and baPWV values with MetS components in males than 
in females and indicate greater arterial stiffness upon 
simultaneously elevated blood pressure, fasting plasma 
glucose, and waist circumference. Therefore, the deter-
mination of arterial stiffness based on CAVI and baPWV 
may be useful for evaluating the cardiovascular risk of 
MetS and its components in Caucasian adults with inter-
mediate cardiovascular risk.
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